<code id='C228277FEE'></code><style id='C228277FEE'></style>
    • <acronym id='C228277FEE'></acronym>
      <center id='C228277FEE'><center id='C228277FEE'><tfoot id='C228277FEE'></tfoot></center><abbr id='C228277FEE'><dir id='C228277FEE'><tfoot id='C228277FEE'></tfoot><noframes id='C228277FEE'>

    • <optgroup id='C228277FEE'><strike id='C228277FEE'><sup id='C228277FEE'></sup></strike><code id='C228277FEE'></code></optgroup>
        1. <b id='C228277FEE'><label id='C228277FEE'><select id='C228277FEE'><dt id='C228277FEE'><span id='C228277FEE'></span></dt></select></label></b><u id='C228277FEE'></u>
          <i id='C228277FEE'><strike id='C228277FEE'><tt id='C228277FEE'><pre id='C228277FEE'></pre></tt></strike></i>

          Home / entertainment / explore

          explore


          explore

          author:leisure time    Page View:86
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In